Search results
-
Enhertu completes its front-line march
… (following neoadjuvant therapy) vs Kadcyla Data at ESMO 2025: 53% reduction in risk of disease … vs chemo + paclitaxel + Herceptin + Perjeta Data at ESMO 2025: pathologic CR 67% vs 53%; PDUFA date 18 May 2026 …
- 05/19/2026 - 19:49 -
ESMO 2025 movers – FDA volte-face to the rescue
ESMO 2025 movers – FDA volte-face to the rescue … in four key studies presented at ESMO. Selected ESMO 2025 risers Company Share movement* … to head against AbbVie’s Elahere . Selected ESMO 2025 fallers Company Share movement* …
- 05/19/2026 - 19:49 -
ESMO 2025 – Sanofi takes aim at Lutathera
ESMO 2025 – Sanofi takes aim at Lutathera … 35% Note: data cutoff 14 Apr 2025. Source: ESMO 2025. Discussing the data in …
- 05/19/2026 - 19:49 -
ESMO 2025 – bemarituzumab fails to convince
ESMO 2025 – bemarituzumab fails to convince …
- 05/19/2026 - 19:49 -
ESMO 2025 – Incyte impresses in KRAS G12D
ESMO 2025 – Incyte impresses in KRAS G12D … KRAS G12D inhibitors in pancreatic cancer at ESMO 2025 INCB161734 HRS-4642 HRS-4642 … & unconfirmed responses; **confirmed responses. Source: ESMO 2025. Conferences Trial …
- 05/19/2026 - 19:49 -
ESMO 2025 – Merck and Daiichi Rejoice over raludotatug
ESMO 2025 – Merck and Daiichi Rejoice over raludotatug … . Source: Dr Isabelle Ray-Coquard & ESMO 2025. Conferences Trial …
- 05/19/2026 - 19:49 -
ESMO 2025 – little solace for Roche’s doomed TIGIT
ESMO 2025 – little solace for Roche’s doomed TIGIT …
- 05/19/2026 - 19:49 -
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
ESMO 2025 – no starring role for Exelixis’s Cabometyx … (95% CI 0.65-0.94) Source: Dr Anwaar Saeed & ESMO 2025. On the question of whether zanzalintinib …
- 05/19/2026 - 19:49 -
ESMO 2025 – more ivonescimab shots on goal for Summit
ESMO 2025 – more ivonescimab shots on goal for Summit …
- 05/19/2026 - 19:49 -
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
ESMO 2025 – Novartis looks for Pluvicto prostate Addition …
- 05/19/2026 - 19:49
